<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900026</url>
  </required_header>
  <id_info>
    <org_study_id>NEWTON CABG (Cardiolink-007)</org_study_id>
    <nct_id>NCT03900026</nct_id>
  </id_info>
  <brief_title>Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery</brief_title>
  <acronym>NEWTON-CABG</acronym>
  <official_title>A Randomized Trial of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (NEWTON-CABG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Applied Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if evolocumab added to regular statin therapy
      improves vein graft patency after coronary artery bypass graft (CABG) surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery bypass graft (CABG) surgery is a procedure in which an artery or vein from
      the body is grafted to a critically narrowed coronary artery to restore flow of oxygenated
      blood to the heart. Statins are frequently prescribed after CABG surgery in order to lower
      LDL cholesterol levels and reduce the chances of coronary artery obstruction recurring.
      Despite this preventive measure, new vein grafts do end up becoming blocked in a significant
      proportion of patients. Evolocumab (Repatha®) is a recently approved medication that has been
      shown to effectively lower LDL cholesterol levels in the blood.

      NEWTON-CABG is an investigator-initiated multicenter, double-blind, randomized,
      placebo-controlled, parallel group study of evolocumab [140mg administered subcutaneously
      (SC) every two weeks (Q2W)] added to statin therapy for 24 months postoperatively in a broad
      population of patients undergoing CABG surgery. Eligible subjects will be randomized to
      receive evolocumab or placebo within 21 days of index CABG. Prior to randomization,
      post-operative patients will be on moderate or high intensity statin therapy (atorvastatin
      40-80mg, rosuvastatin 20-40mg or simvastatin 40mg daily unless another statin/dose or
      non-statin alternative is clinically justified). A CTAngiogram will be conducted at 24 months
      following CABG. Routine study visits will be done 3, 6, 12, 18 and 24 months post-surgery.

      This study is supported by Amgen Inc.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, double-blind, randomized, placebo-controlled, parallel group study of evolocumab.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saphenous vein graft disease rate (VGDR)</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Saphenous vein graft disease rate (VGDR) is defined as the proportion of vein grafts with significant stenosis or total occlusion (≥50%) on 64-slice (or greater) cardiac CT angiography (CTA) or clinically indicated coronary angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with at least 1 vein graft totally (100%) occluded.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Proportion of patients who have at least 1 totally (100%) occluded vein graft at 24 months post CABG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of vein grafts which are totally (100%) occluded grafts.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Percentage of vein grafts that are totally (100%) occluded at 24 months post CABG.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Composite rate of fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, cardiovascular death, coronary heart disease death, repeat coronary revascularization</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>composite rate of occurrence of the above mentioned clinical outcomes at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of fatal and non-fatal myocardial infarction.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of fatal and non-fatal stroke.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of cardiovascular death.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of coronary heart disease death.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of repeat coronary revascularization.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of all-cause mortality.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Proportion of patients who have died at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of total vein graft patency at 24 months.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Rate of total vein graft patency defined as 1-VGDR at 24 months post CABG.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients free of vein graft disease at 24 months.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Percentage of patients who are free of vein graft disease at 24 months defined as having no vein grafts with ≥ 50% stenosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vein graft plaque volume.</measure>
    <time_frame>24 months post CABG</time_frame>
    <description>Volume of vein graft plaque at 24 months post CABG.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">766</enrollment>
  <condition>Coronary Artery Bypass Graft Surgery</condition>
  <condition>Atherosclerosis</condition>
  <condition>Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection</description>
    <arm_group_label>Evolocumab Treatment</arm_group_label>
    <other_name>Repatha®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - To be considered eligible for participation in this study, a
        participant must satisfy each of the following criteria:

          1. Age ≥ 18 years

          2. Scheduled to undergo coronary artery bypass graft (CABG) surgery (with or without
             cardiopulmonary bypass (CPB); with or without single valve repair/replacement)

          3. CABG procedure included/planned to include at least two saphenous vein grafts

          4. CABG procedure occurred within the past 21 days, or is planned within the next 60 days

          5. On a moderate to high intensity statin therapy (defined as atorvastatin 40-80mg daily,
             rosuvastatin 20-40mg or simvastatin 40mg daily) unless a lower dose, or another statin
             or non-statin therapy is clinically justified

        Exclusion Criteria - A participant will be ineligible for participation in this study if he
        or she satisfies any one or more of the following criteria:

          1. Patients in whom additional lowering of LDL-C with evolocumab is deemed to be
             clinically inappropriate

          2. Allergy to contrast dye

          3. Known severe hepatic impairment (Childs-Pugh, Class C).

          4. Known renal disease with estimated glomerular filtration rate (eGFR) &lt; 30
             mL/min/1.73m2

          5. Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow)

          6. Use of cholesterylester transfer protein (CETP) inhibition treatment within 12 months
             prior to randomization.

          7. Current, prior within past year, or known planned use of PCSK9 inhibition treatment

          8. Severe cardiovascular or concomitant non-cardiovascular disease that is expected to
             reduce life expectancy to less than 2 years

          9. Major active infection, or major hematologic, renal, respiratory, metabolic,
             gastrointestinal or endocrine dysfunction

         10. Women who are pregnant or breastfeeding

         11. Women of child bearing potential who are unwilling to use proper family planning or
             birth control methods to avoid pregnancy. Women are considered post-menopausal and not
             of childbearing potential after 12 months of natural (spontaneous) amenorrhea or have
             had a surgical procedure such as hysterectomy which makes pregnancy impossible.

         12. Known intolerance or allergy to evolocumab or other PCSK9 inhibitors.

         13. Currently taking simvastatin &gt;40mg/day, niacin or bile acid sequestrants

         14. Known latex allergy

         15. Inability to comply with protocol-required study visits or procedures, including
             administration of study drug

         16. Known history of cancer within the past 5 years (except for carcinoma in-situ of the
             cervix, stage 1 prostate cancer or adequately treated non-melanoma carcinomas of the
             skin)

         17. Participation in another investigational device or drug study which is likely to
             affect the primary outcome, within 30 days of planned initiation of study drug

         18. NYHA class IV

         19. Pacemaker or other implantable device implanted within 30 days prior to screening

        Additional postoperative exclusion criteria:

          1. Received only &lt;2 vein grafts

          2. Major peri-operative complications following CABG surgery (e.g. stroke, MI, renal
             failure requiring dialysis, or postoperative ICU stay &gt; 5 days) prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mazer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Subodh Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Leiter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danusha Nandamalavan</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>77038</phone_ext>
    <email>NandamalavaD@smh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Kunze</last_name>
      <phone>203-737-2150</phone>
      <email>kim.kunze@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Umer Darr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Burns</last_name>
      <phone>904-576-0166</phone>
      <email>heathburns@encoredocs.com</email>
    </contact>
    <investigator>
      <last_name>Michael Koren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsey Gallant</last_name>
      <email>WIGHTA@mmc.org</email>
    </contact>
    <contact_backup>
      <phone>207-662-1489</phone>
    </contact_backup>
    <investigator>
      <last_name>Robert Kramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maliha Muneer</last_name>
      <phone>780-407-8614</phone>
      <email>muneer@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Shaw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Mullen</last_name>
      <phone>905.521.2100</phone>
      <phone_ext>44342</phone_ext>
      <email>Courtney.Mullen@phri.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Whitlock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah DuMerton</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>3224</phone_ext>
      <email>Deborah.DuMerton@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Tarit Saha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shira Brodutch</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>49419</phone_ext>
      <email>Shira.Brodutch@unityhealth.to</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Tremblay</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3797</phone_ext>
      <email>hugo.tremblay@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Francois Dagenais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Maier</last_name>
      <email>Karen.Maier@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Alex Gregory</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Bypass Surgery</keyword>
  <keyword>CABG</keyword>
  <keyword>Saphenous Vein Graft</keyword>
  <keyword>Evolocumab</keyword>
  <keyword>Repatha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

